Nibec Co Ltd
Nibec Co Ltd is a South Korean biotechnology company focused on pharmaceuticals and medical research, primarily generating revenue through the development and commercialization of biopharmaceutical products.
Business. Nibec Co Ltd (138610.KQ) is a biotechnology and medical research company engaged in pharmaceuticals and medical research activities. The firm is listed on the KOSDAQ exchange. Specific details regarding operating segments, headquarters location, and geographic revenue mix are not available in the provided data.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
Nibec Co Ltd (138610.KQ) is a biotechnology and medical research company engaged in pharmaceuticals and medical research activities. The firm is listed on the KOSDAQ exchange. Specific details regarding operating segments, headquarters location, and geographic revenue mix are not available in the provided data.
Nibec maintains a strong capital structure with a debt-to-equity ratio of 0.22, indicating a relatively low reliance on debt financing. The company's liquidity position is characterized as medium risk, with a current ratio of 3.16, suggesting it has sufficient short-term assets to cover its liabilities. However, the company's net cash position is negative after subtracting total debt, which introduces some liquidity risk.
In terms of profitability, Nibec's return on equity (ROE) of 10.13% and return on assets (ROA) of 7.37% are strong indicators of efficient capital utilization and asset management. These metrics suggest the company is generating solid returns relative to its equity and total assets, which is favorable compared to the industry's typical performance benchmarks.
The company's revenue is concentrated in a single business segment, as disclosed in its financial statements, with no geographic diversification provided in the available data. This lack of diversification could expose the company to higher operational and market risks if its primary market or product line experiences a downturn.
Nibec's growth trajectory is supported by a positive operating cash flow of 5.82 billion KRW and a free cash flow of 2.79 billion KRW, indicating the company is generating sufficient cash to fund operations and potentially reinvest in growth opportunities. However, the company's capital expenditure of -5.27 billion KRW suggests a net reduction in capital spending, which may indicate a strategic shift or a focus on cost optimization.
The company's risk profile is marked by a medium liquidity risk and a low dilution risk. The risk assessment highlights the negative net cash position after subtracting total debt as a key flag, which could impact the company's ability to meet short-term obligations without external financing. The dilution risk is low, and no significant adjustments have been applied to the valuation metrics, suggesting the company's capital structure is stable.
Recent events and disclosures indicate that Nibec's last actual EPS was -310.00 KRW, as reported in analyst estimates. This negative EPS suggests the company may be facing challenges in maintaining profitability, which could be a concern for investors and stakeholders.
- Nibec maintains a strong capital structure with a low debt-to-equity ratio of 0.22.
- The company's ROE of 10.13% and ROA of 7.37% indicate efficient capital and asset utilization.
- Nibec's liquidity position is medium risk, with a current ratio of 3.16.
- The company's revenue is concentrated in a single business segment, with no geographic diversification disclosed.
- Nibec's recent EPS of -310.00 KRW suggests potential challenges in maintaining profitability.
Bull / Bear case
Generated · model-assistedIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- Nibec Co Ltd Market data — financials · 2026-05-26
- Nibec Co Ltd Market data — analyst estimates · 2026-05-26